Physician profile
Philip Gilly
NPI 1609849868
$2,473.08
in general payments reported to CMS, 2019-2025
15 companies · $928 in 2025
The $928 reported for 2025 was more than what 88% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $60.75 · 2021: $17.85 · 2022: $89.77 · 2023: $436 · 2024: $551 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,914.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $555.07 | 2019-2025 | Sublocade |
| Alkermes, INC. | $311.24 | 2022-2025 | Aristada, Vivitrol, Lybalvi |
| Braeburn INC. | $309.25 | 2024-2025 | Brixadi |
| Orexo US, INC. | $278.79 | 2019-2025 | Zubsolv |
| Abbvie INC. | $248.29 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $184.99 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $121.83 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $97.48 | 2019 | |
| Amgen INC. | $93.17 | 2019 | |
| Uswm, LLC | $89.86 | 2023 | Lucemyra |
| Neurocrine Biosciences, INC. | $80.45 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $50.67 | 2022-2023 | Austedo, Uzedy |
| Titan Pharmaceuticals, INC. | $17.61 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.32 | 2024 | Invega Sustenna |
| Exact Sciences Corporation | $17.06 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Gilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.